Citations 2
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
Kalman, LV, Agúndez, JAG, Appell, Malin Lindqvist , Black, J.H., Bell, GC, Boukouvala, Sotiria , Bruckner, Carsten, Bruford, Elspeth A. , Caudle, KE, Coulthard, SA, Daly, Ann K. , Tredici, AL Del, Dunnen, Johan T. den , Drozda, Katarzyna, Everts, Robin E. , Flockhart, David A., Freimuth, Robert R. , Hachad, Houda , Hartshorne, Toinette, Ingelman‐Sundberg, Magnus , Klein, Teri E. , Lauschke, Volker M. , Maglott, DR, McLeod, HL, McMillin, GA, Ua, Meyer, Dj, Müller, Nickerson, D. A., Oetting, WS , Pacanowski, MA, Vm, Pratt, Relling, MV, Roberts, Angharad M. , Ws, Rubinstein, Sangkuhl, Katrin , Schwab, Matthias , Scott, Stuart A. , Sim, SC, Thirumaran, RK, Toji, LH, Tyndale, Rachel F. , Schaik, RHN van, Whirl‐Carrillo, Michelle , Yeo, K. L. B., Zanger, UM, Agúndez, José A. G. , Müller, Daniel J. , Agúndez, JAG, Gaedigk, Andrea , Relling, Mary V. , Toji, Lorraine H., Whirl-Carrillo, Michelle , Agúndez, José A G , Hachad, Houda , Müller, Daniel J , Tyndale, Rachel F , Freimuth, Robert R , Klein, Teri E , Scott, Stuart A , Schwab, Matthias
Clinical Pharmacology & Therapeutics | October 20, 2015 | Volume: 99 | Issue: 2 | Pages: 172-185
This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J K, Bishop, JR, Dj, Müller, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, Adrián , Skaar, TC, Scott, Stuart A. , Stingl, Julia , Klein, Teri E. , Caudle, KE, Leeder, J. Steven , Müller, Daniel J. , Sangkuhl, Katrin , Ji, Yuan , Skaar, T.C., Gaedigk, Andrea , LLerena, Adrián , Müller, Daniel J , Klein, Teri E , Scott, Stuart A
Clinical Pharmacology & Therapeutics | May 13, 2015 | Volume: 98 | Issue: 2 | Pages: 127-134
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org ).